Lepodisiran (LY3819469) is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran can be used in studies related to atherosclerotic cardiovascular disease [1].
In Vivo, Lepodisiran (single dose) safely reduces lipoprotein (a) levels by up to 94% with durable efficacy.
References:
[1]. Nissen S E, et al. Lepodisiran—a long-duration small interfering RNA targeting lipoprotein (a)[J]. New England Journal of Medicine, 2025, 392(17): 1673-1683.
In Vivo, Lepodisiran (single dose) safely reduces lipoprotein (a) levels by up to 94% with durable efficacy.
References:
[1]. Nissen S E, et al. Lepodisiran—a long-duration small interfering RNA targeting lipoprotein (a)[J]. New England Journal of Medicine, 2025, 392(17): 1673-1683.